HighPoint Advisor Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.66M | Buy |
5,555
+152
| +3% | +$155K | 0.23% | 88 |
|
|
2026
Q1 | $4.97M | Sell |
5,403
-18,697
| -78% | -$19M | 0.21% | 101 |
|
|
2025
Q4 | $25.9M | Buy |
24,100
+5,301
| +28% | +$5.07M | 0.57% | 33 |
|
|
2025
Q3 | $14.3M | Sell |
18,799
-397
| -2% | -$295K | 0.68% | 27 |
|
|
2025
Q2 | $15M | Buy |
19,196
+122
| +0.6% | +$94.8K | 0.8% | 23 |
|
|
2025
Q1 | $16.9M | Buy |
19,074
+333
| +2% | +$277K | 0.98% | 20 |
|
|
2024
Q4 | $16.1M | Sell |
18,741
-1,294
| -6% | -$1.07M | 0.87% | 21 |
|
|
2024
Q3 | $17.7M | Sell |
20,035
-1,019
| -5% | -$916K | 1.03% | 17 |
|
|
2024
Q2 | $16.6M | Buy |
21,054
+3,918
| +23% | +$3.13M | 0.99% | 18 |
|
|
2024
Q1 | $13M | Buy |
17,136
+190
| +1% | +$135K | 0.92% | 18 |
|
|
2023
Q4 | $13.1M | Buy |
+16,946
| New | +$9.89M | 0.94% | 18 |
|
|
2022
Q2 | $3.82M | Buy |
+11,579
| New | +$3.48M | 0.42% | 49 |
|
|
2021
Q3 | $2.54M | Sell |
10,990
-907
| -8% | -$224K | 0.25% | 82 |
|
|
2021
Q2 | $2.73M | Buy |
11,897
+2,326
| +24% | +$467K | 0.28% | 79 |
|
|
2021
Q1 | $1.77M | Buy |
9,571
+686
| +8% | +$134K | 0.2% | 99 |
|
|
2020
Q4 | $1.79M | Buy |
8,885
+580
| +7% | +$86.6K | 0.22% | 92 |
|
|
2020
Q3 | $1.21M | Sell |
8,305
-325
| -4% | -$50.3K | 0.22% | 94 |
|
|
2020
Q2 | $1.41M | Sell |
8,630
-196
| -2% | -$30.1K | 0.3% | 73 |
|
|
2020
Q1 | $1.44M | Sell |
8,826
-386
| -4% | -$53K | 0.34% | 65 |
|
|
2019
Q4 | $1.3M | Buy |
9,212
+645
| +8% | +$74.8K | 0.27% | 75 |
|
|
2019
Q3 | $972K | Buy |
8,567
+966
| +13% | +$108K | 0.21% | 85 |
|
|
2019
Q2 | $815K | Sell |
7,601
-2,290
| -23% | -$270K | 0.19% | 98 |
|
|
2019
Q1 | $1.14M | Sell |
9,891
-544
| -5% | -$66.2K | 0.28% | 75 |
|
|
2018
Q4 | $1.27M | Buy |
10,435
+2,470
| +31% | +$276K | 0.34% | 66 |
|
|
2018
Q3 | $892K | Buy |
7,965
+143
| +2% | +$14.3K | 0.24% | 99 |
|
|
2018
Q2 | $816K | Sell |
7,822
-694
| -8% | -$57K | 0.22% | 120 |
|
|
2018
Q1 | $733K | Buy |
8,516
+416
| +5% | +$33.5K | 0.2% | 131 |
|
|
2017
Q4 | $617K | Buy |
8,100
+232
| +3% | +$19.7K | 0.18% | 142 |
|
|
2017
Q3 | $654K | Sell |
7,868
-663
| -8% | -$54.4K | 0.2% | 134 |
|
|
2017
Q2 | $702K | Hold |
8,531
| – | – | 0.23% | 117 |
|
|
2017
Q1 | $702K | Buy |
8,531
+359
| +4% | +$28.8K | 0.23% | 117 |
|
|
2016
Q4 | $685K | Sell |
8,172
-669
| -8% | -$49.8K | 0.22% | 125 |
|
|
2016
Q3 | $687K | Sell |
8,841
-5,328
| -38% | -$426K | 0.24% | 102 |
|
|
2016
Q2 | $1.16M | Buy |
14,169
+3,317
| +31% | +$250K | 0.41% | 66 |
|
|
2016
Q1 | $844K | Sell |
10,852
-4,272
| -28% | -$323K | 0.52% | 53 |
|
|
2015
Q4 | $1.25M | Buy |
15,124
+3,673
| +32% | +$305K | 0.82% | 27 |
|
|
2015
Q3 | $958K | Sell |
11,451
-2,879
| -20% | -$243K | 1.06% | 25 |
|
|
2015
Q2 | $1.2M | Sell |
14,330
-801
| -5% | -$61K | 1.85% | 19 |
|
|
2015
Q1 | $1.12M | Buy |
+15,131
| New | +$1.08M | 1.71% | 30 |
|
Other funds holding LLY
HighPoint Advisor Group's LLY Position: Q2 2026 in Review
HighPoint Advisor Group increased its Eli Lilly (LLY) stake by 2.8% in Q2 2026, buying an estimated $155K and bringing the position to 5,555 shares worth $6.66M. The position accounts for 0.23% of the portfolio, ranked #88.
HighPoint Advisor Group first reported a position in LLY in Q1 2015 and has held it in 39 quarters since. The position peaked at $25.9M in Q4 2025. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- HighPoint Advisor Group held 5,555 shares of Eli Lilly worth $6.66M as of Q2 2026.
- HighPoint Advisor Group bought 152 Eli Lilly shares in Q2 2026, an estimated $155K.
- Eli Lilly made up 0.23% of HighPoint Advisor Group's portfolio in Q2 2026, its #88 holding.
- HighPoint Advisor Group first reported a position in Eli Lilly in Q1 2015 and has held it in 39 quarters since.
- HighPoint Advisor Group's Eli Lilly position peaked at $25.9M in Q4 2025.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on HighPoint Advisor Group's 13F filing for Q2 2026, filed 5 Aug 2026.